Swiss cannabis operator with EU-GMP compliant facility seeks strategic partner to become a dominant force in the EU

A Swiss pharma-centric medical cannabis company specializing in indoor production and distribution of premium, high-quality, medical cannabis flowers

The company operates in a purpose built, 10,000 m² leased facility, featuring 25 grow rooms, state-of-the-art chemistry and biology labs, and a GMP-certified cleanroom for microbiological testing of finished products.

The company is currently operating the initial production phase and is generating revenue with secured contracts totaling CHF 7 million

Full production commences in Q1 2025, with expected sales ramping up to CHF 40 million and a target of CHF 70 million by 2026 through the addition of cannabis extraction and branded product launches

Has invested between 60 and 70 million CHF to build out the entire site

Company is waiting to obtain EU-GMP certification, which is expected imminently

Experienced, industry-leading international team with deep expertise navigating global medical cannabis markets

Company aims to secure a leading position in the DACH region (Germany, Austria and Switzerland) and globally, emphasizing R&D and sustainability to establish a strong position in the medical cannabis market and build consumer trust through the promotion of cannabis-based health benefits

Company has secured several initial offtake agreements, ensuring timely, efficient and continuous production and distribution of medical cannabis

Investing in the company will facilitate the development of a full-scale production process and secure additional offtake agreements to fully utilize the annual capacity of 18 tons

Seeking an equity partner to invest up to 6 million CHF in exchange for a stake in the company, with funds allocated to launch GMP-certified indoor cannabis production facility. Open for bridge loan or full divestiture opportunities.